Our Pricing

Mounjaro vs Orlistat UK Comparison Guide

Published on: June 03, 2026

When comparing mounjaro vs orlistat UK comparison options, understanding the fundamental differences between these two licensed weight loss treatments is essential for making an informed decision. Mounjaro (tirzepatide) and Orlistat represent two distinct approaches to weight management: one works through hormonal appetite regulation, the other through fat absorption blocking. Both require clinical assessment by a UK prescriber and are available through Cured Pharmacy with transparent upfront pricing and expert pharmaceutical support.

How Mounjaro and Orlistat Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. It works by mimicking two natural gut hormones that regulate appetite, slow gastric emptying, and improve insulin sensitivity. Administered as a once-weekly subcutaneous injection, Mounjaro addresses weight loss at a hormonal level, reducing hunger signals and increasing satiety after meals.

Orlistat, by contrast, is a lipase inhibitor that works entirely within the digestive system [2]. Taken orally three times daily with meals, it blocks approximately 30% of dietary fat from being absorbed in the intestines. The unabsorbed fat is then excreted naturally. Unlike Mounjaro, Orlistat does not affect appetite hormones or brain signalling—it purely prevents fat digestion. This fundamental difference in mechanism means the two treatments suit different patient profiles and produce distinct side effect patterns.

The choice between these mechanisms often depends on your eating habits, medical history, and weight loss goals. Patients who struggle with appetite control and frequent hunger may benefit more from Mounjaro's hormonal approach, whilst those who consume high-fat diets and prefer oral medication may find Orlistat more suitable, subject to prescriber assessment.

Clinical Efficacy: Mounjaro vs Orlistat Weight Loss Results

Clinical trial data reveals substantial differences in weight loss outcomes between these treatments. In the SURMOUNT-1 trial, participants taking the highest Mounjaro dose (15mg weekly) achieved an average body weight reduction of 22.5% over 72 weeks [1]. Even at the lowest maintenance dose (5mg), average weight loss exceeded 15% of initial body weight. These results represent some of the highest efficacy figures recorded for any pharmacological weight loss intervention.

Orlistat demonstrates more modest but clinically meaningful results. Meta-analyses of multiple trials show that Orlistat users typically achieve an additional 2.9kg weight loss compared to placebo over 12 months, when combined with a reduced-calorie diet [2]. This translates to approximately 3-5% additional body weight reduction beyond diet and lifestyle changes alone. Whilst lower than Mounjaro's figures, this level of weight loss can still produce significant health benefits, including improvements in blood pressure, cholesterol, and diabetes risk markers.

It's important to note that both treatments require commitment to lifestyle modifications. Mounjaro's superior efficacy comes with higher cost and injection-based delivery, whilst Orlistat requires strict dietary fat restriction to minimise gastrointestinal side effects. Your UK prescriber will assess which treatment aligns best with your medical profile, weight loss targets, and lifestyle preferences during your clinical consultation.

Long-Term Weight Maintenance Considerations

Weight maintenance after initial loss differs between treatments. Mounjaro users typically continue treatment long-term to maintain hormonal appetite regulation, with ongoing prescription required [3]. Discontinuation often leads to gradual weight regain as appetite signals return to baseline. Orlistat can be used intermittently or continuously, and some patients successfully transition to maintenance through sustained dietary changes alone. Both approaches require ongoing clinical monitoring to optimise outcomes and adjust treatment plans as needed.

Side Effects and Tolerability Profile

Mounjaro's side effect profile centres primarily on gastrointestinal symptoms, particularly during dose escalation. The most commonly reported effects include nausea (occurring in 20-30% of patients), diarrhoea, constipation, and occasional vomiting [1]. These symptoms typically diminish over 4-8 weeks as the body adapts to treatment. The gradual dose titration protocol—starting at 2.5mg and increasing every four weeks—is specifically designed to improve tolerability. More serious but rare risks include pancreatitis and gallbladder complications, which your prescriber will discuss during assessment.

Orlistat produces distinctly different side effects related to its mechanism of blocking fat absorption. The most common issues are gastrointestinal: oily spotting, flatulence with discharge, urgent bowel movements, and fatty or oily stools [2]. These effects are directly proportional to dietary fat intake—consuming more than 15-20g of fat per meal significantly increases symptom severity. Many patients find these effects socially disruptive, though they can be managed effectively through strict dietary fat restriction. Unlike Mounjaro, Orlistat does not carry risks of pancreatitis or thyroid concerns.

Tolerability often determines treatment adherence. Patients who cannot tolerate injection-based delivery or experience persistent nausea with GLP-1 medications may prefer Orlistat's oral format, despite its gastrointestinal demands. Conversely, those who find Orlistat's side effects too disruptive or who struggle with three-times-daily dosing often achieve better adherence with Mounjaro's once-weekly injection. Your clinical assessment will explore your previous medication experiences to guide appropriate selection.

Eligibility Criteria and Prescribing Guidelines in the UK

NICE guidelines and MHRA licensing determine who can be prescribed each treatment in the UK. Mounjaro is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia [4]. Certain medical conditions preclude Mounjaro use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastroparesis. Pregnancy and breastfeeding are absolute contraindications.

Orlistat has broader eligibility criteria and fewer absolute contraindications. It is licensed for adults with BMI 30 kg/m² or above, or 28 kg/m² or above with associated risk factors [2]. The lower BMI threshold and oral delivery make Orlistat accessible to patients who don't meet criteria for injectable treatments or who have medical conditions that preclude GLP-1 use. However, Orlistat is contraindicated in chronic malabsorption syndromes, cholestasis, and during pregnancy. Patients taking certain medications, including warfarin and levothyroxine, require careful monitoring due to potential interactions.

During your free online consultation at Cured Pharmacy, a UK-registered prescriber will review your complete medical history, current medications, and weight loss goals to determine which treatment is clinically appropriate and safe. This assessment typically takes under three minutes but ensures full compliance with MHRA prescribing standards and patient safety protocols.

Special Population Considerations

Certain patient groups require additional consideration when choosing between treatments. Patients with type 2 diabetes often benefit more from Mounjaro's dual action on blood glucose regulation, whilst those with fat-soluble vitamin deficiencies may be better suited to Mounjaro rather than Orlistat, which can impair vitamin A, D, E, and K absorption [2]. Older adults and those with mobility limitations may prefer Orlistat's oral format over self-injection, though proper injection training typically resolves these concerns.

Cost Comparison and Value Considerations

Mounjaro is available at Cured Pharmacy from £124.99 per month, depending on your prescribed dose. This includes the KwikPen injection device, all needles, and pharmaceutical support throughout treatment. Whilst representing a higher upfront investment than oral alternatives, Mounjaro's superior efficacy—with average weight loss of 15-22.5% in clinical trials—may provide better value for patients seeking substantial weight reduction [1].

Orlistat presents a more accessible entry point for weight loss treatment, with competitive UK pricing and lower monthly costs than injectable options. The three-times-daily dosing schedule means a month's supply involves more frequent administration than Mounjaro's once-weekly injection. When evaluating cost-effectiveness, consider not just the medication price but also the expected weight loss magnitude, treatment duration required to reach goals, and your ability to adhere to each treatment's specific demands.

Both treatments require ongoing prescription and clinical monitoring. At Cured Pharmacy, pricing is transparent and displayed upfront before your consultation, with no hidden fees. Your prescriber will discuss treatment duration expectations during your assessment, as this significantly impacts total cost. Many patients achieve their target weight loss within 6-12 months, though individual timelines vary based on starting weight, adherence, and metabolic factors.

Making Your Choice: Which Treatment Suits You Best?

The decision between Mounjaro and Orlistat depends on multiple factors beyond efficacy alone. Consider Mounjaro if you have significant weight to lose (typically 20kg or more), struggle with appetite control and frequent hunger, prefer once-weekly dosing, and can manage injection-based delivery. Mounjaro's hormonal mechanism addresses the underlying drivers of overeating, making it particularly effective for patients with strong appetite signals or emotional eating patterns [3].

Orlistat may be more suitable if you prefer oral medication, consume a diet naturally lower in fat, have contraindications to GLP-1 medications, or are working with a smaller weight loss target. The treatment works best for patients who can commit to dietary fat restriction (under 15g per meal) and who view the gastrointestinal side effects as a behavioural feedback mechanism rather than an intolerable burden. Some patients successfully use Orlistat as a stepping stone, establishing healthier eating habits before potentially progressing to more intensive treatments if needed.

Your UK prescriber at Cured Pharmacy will guide this decision through a comprehensive clinical assessment. Factors including your medical history, previous weight loss attempts, current medications, lifestyle patterns, and personal preferences all inform the recommendation. Many patients benefit from trying one approach first, with the option to reassess and adjust if initial results or tolerability don't meet expectations. The goal is sustainable weight loss that integrates successfully into your daily life.

Starting Your Weight Loss Journey with Cured Pharmacy

Beginning treatment involves a free online consultation that takes under three minutes to complete. You'll provide your medical history, current health status, and weight loss goals. A UK-registered prescriber reviews your assessment, typically within hours, and determines which treatment is clinically appropriate. If approved, your medication is dispensed by our GPhC-registered pharmacy team and delivered in discreet packaging directly to your door. Ongoing support from Superintendent Pharmacist Tarun Kumar (GPhC 2233073) and the clinical team ensures you have expert guidance throughout your treatment journey.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. (2007). Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ, 335(7631), 1194–1199. https://doi.org/10.1136/bmj.39385.413113.25 [accessed 13 August 2026]
3. Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating overweight and obesity [TA1069]. NICE. https://www.nice.org.uk/guidance/ta1069 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro and Orlistat are prescription-only medicines that must be used under medical supervision. Individual results may vary, and weight loss outcomes depend on adherence to treatment protocols and lifestyle modifications.